Literature DB >> 92620

Emergence of trimethoprim-resistant enterobacteria in patients receiving long-term co-trimoxazole for the control of intractable urinary-tract infection.

N J Pearson, K J Towner, A M McSherry, W R Cattell, F O'Grady.   

Abstract

In patients with previously intractable urinary-tract infection treated with low-dose co-trimoxazole for 6--58 (mean 32.7) months, the percentage of infected urines fell from 41.4 before treatment to 6.3 during treatment. Only 6 episodes of infection were due to trimethoprim-resistant bacteria. Results in a small group of patients in whom treatment was continued with trimethoprim alone were similar. Under the conditions of this study, long-term control of urinary-tract infection was not materially compromised by breakthrough infections due to trimethoprim-resistant organisms.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 92620     DOI: 10.1016/s0140-6736(79)92331-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Bacterial resistance to trimethoprim.

Authors: 
Journal:  Br Med J       Date:  1980-08-30

Review 2.  Trimethoprim: a review of its antibacterial activity, pharmacokinetics and therapeutic use in urinary tract infections.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

3.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

4.  Acute lymphoblastic leukaemia: trimethoprim resistant organisms during treatment.

Authors:  H P McDowell; P Shears; C A Hart; J Martin
Journal:  Arch Dis Child       Date:  1987-06       Impact factor: 3.791

Review 5.  Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy.

Authors:  G P Wormser; G T Keusch; R C Heel
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.